File Download
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Hepatitis B surface antigen kinetics during 10 years of virologic suppression with nucleoside analogue therapy
Title | Hepatitis B surface antigen kinetics during 10 years of virologic suppression with nucleoside analogue therapy |
---|---|
Authors | |
Keywords | Medical sciences Gastroenterology |
Issue Date | 2012 |
Publisher | Wiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH |
Citation | The 2012 Asian Pacific Digestive Week (APDW 2012), Bangkok, Thailand, 5–8 December 2012. In Journal of Gastroenterology and Hepatology, 2012, v. 27 suppl. S5, p. 257, abstract P11-162 How to Cite? |
Abstract | BACKGROUND: The kinetics of serum hepatitis B surface antigen (HBsAg) levels during long-term nucleoside analogue therapy has not been described. METHODS: We recruited 71 patients achieving persistent viro-logic suppression (Serum HBV DNA < 2,000 IU/mL) during lamivudine therapy for at least 10 years (10 patients for 15 years). Serum HBsAg (Elecsys HBsAg II) and HBV DNA levels (Cobas Taqman) were determined at baseline, year 5 and year 10. HBV genotype was determined by a line probe assay. RESULTS: The median age at lamivudine commencement was 38.6 (range 13.1 to 66.7) years. 57 patients (78.1%) were male and 43 (58.9%) were hepatitis B e antigen (HBeAg)-positive, with all 43 patients achieving HBeAg seroconversion after a median period of 2.82 (range 0.13 to 10.85) months. There was no significant difference in the median annual HBsAg decline rate from baseline to year 5 and from year 5 to 10 (0.350 and 0.359 log IU/mL/year respectively, p = 0.749). There was no difference in median annual HBsAg decline when comparing baseline HBeAg-positive and negative patients (0.111 and 0.064 log IU/ mL/year respectively, p = 0.165), genotypes B and C (0.081 and 0.125 log IU/mL/year respectively, p = 0.170), and persistent undetectable viremia versus intermediate levels of viremia of 20–2000 IU/mL (0.081 and 0.124 log IU/mL/year respectively, p = 0.232).7 patients (9.6% 4 HBeAg-positive and 3 HBeAg-negative) achieved HBsAg seroclearance after a median period of 7.59 (range 3.59 to 12.15) years. The 7 patients achieving HBsAg seroclearance, when compared to the remaining 64 patients, had a lower median baseline HBsAg level (2.72 and 3.67 log IU/mL respectively, p = 0.029) and a significantly larger HBsAg decline (0.401 log IU/mL/year versus 0.081 log IU/mL respectively, p < 0.001) CONCLUSION: HBsAg reduction remained relatively stable during long-term lamivudine therapy. A low baseline HBsAg level and an increased HBsAg decline rate would be a pre-requisite for subsequent HBsAg seroclearance. |
Description | This journal suppl. entatiled: Special Issue: Asian Pacific Digestive Week 2012 ... Poster Presentation 11. Liver: no. P11-162 |
Persistent Identifier | http://hdl.handle.net/10722/186845 |
ISSN | 2023 Impact Factor: 3.7 2023 SCImago Journal Rankings: 1.179 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Seto, WK | en_US |
dc.contributor.author | Wong, DKH | en_US |
dc.contributor.author | Fung, J | en_US |
dc.contributor.author | Lai, CL | en_US |
dc.contributor.author | Yuen, MF | en_US |
dc.date.accessioned | 2013-08-20T12:21:13Z | - |
dc.date.available | 2013-08-20T12:21:13Z | - |
dc.date.issued | 2012 | en_US |
dc.identifier.citation | The 2012 Asian Pacific Digestive Week (APDW 2012), Bangkok, Thailand, 5–8 December 2012. In Journal of Gastroenterology and Hepatology, 2012, v. 27 suppl. S5, p. 257, abstract P11-162 | en_US |
dc.identifier.issn | 0815-9319 | - |
dc.identifier.uri | http://hdl.handle.net/10722/186845 | - |
dc.description | This journal suppl. entatiled: Special Issue: Asian Pacific Digestive Week 2012 ... | - |
dc.description | Poster Presentation 11. Liver: no. P11-162 | - |
dc.description.abstract | BACKGROUND: The kinetics of serum hepatitis B surface antigen (HBsAg) levels during long-term nucleoside analogue therapy has not been described. METHODS: We recruited 71 patients achieving persistent viro-logic suppression (Serum HBV DNA < 2,000 IU/mL) during lamivudine therapy for at least 10 years (10 patients for 15 years). Serum HBsAg (Elecsys HBsAg II) and HBV DNA levels (Cobas Taqman) were determined at baseline, year 5 and year 10. HBV genotype was determined by a line probe assay. RESULTS: The median age at lamivudine commencement was 38.6 (range 13.1 to 66.7) years. 57 patients (78.1%) were male and 43 (58.9%) were hepatitis B e antigen (HBeAg)-positive, with all 43 patients achieving HBeAg seroconversion after a median period of 2.82 (range 0.13 to 10.85) months. There was no significant difference in the median annual HBsAg decline rate from baseline to year 5 and from year 5 to 10 (0.350 and 0.359 log IU/mL/year respectively, p = 0.749). There was no difference in median annual HBsAg decline when comparing baseline HBeAg-positive and negative patients (0.111 and 0.064 log IU/ mL/year respectively, p = 0.165), genotypes B and C (0.081 and 0.125 log IU/mL/year respectively, p = 0.170), and persistent undetectable viremia versus intermediate levels of viremia of 20–2000 IU/mL (0.081 and 0.124 log IU/mL/year respectively, p = 0.232).7 patients (9.6% 4 HBeAg-positive and 3 HBeAg-negative) achieved HBsAg seroclearance after a median period of 7.59 (range 3.59 to 12.15) years. The 7 patients achieving HBsAg seroclearance, when compared to the remaining 64 patients, had a lower median baseline HBsAg level (2.72 and 3.67 log IU/mL respectively, p = 0.029) and a significantly larger HBsAg decline (0.401 log IU/mL/year versus 0.081 log IU/mL respectively, p < 0.001) CONCLUSION: HBsAg reduction remained relatively stable during long-term lamivudine therapy. A low baseline HBsAg level and an increased HBsAg decline rate would be a pre-requisite for subsequent HBsAg seroclearance. | - |
dc.language | eng | en_US |
dc.publisher | Wiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH | - |
dc.relation.ispartof | Journal of Gastroenterology and Hepatology | en_US |
dc.rights | The definitive version is available at www3.interscience.wiley.com | - |
dc.subject | Medical sciences | - |
dc.subject | Gastroenterology | - |
dc.title | Hepatitis B surface antigen kinetics during 10 years of virologic suppression with nucleoside analogue therapy | en_US |
dc.type | Conference_Paper | en_US |
dc.identifier.email | Seto, WK: wkseto2@hku.hk | en_US |
dc.identifier.email | Wong, DKH: danywong@hku.hk | en_US |
dc.identifier.email | Fung, J: jfung@hkucc.hku.hk | en_US |
dc.identifier.email | Lai, CL: hrmelcl@hku.hk | en_US |
dc.identifier.email | Yuen, MF: mfyuen@hku.hk | en_US |
dc.identifier.authority | Seto, WK=rp01659 | en_US |
dc.identifier.authority | Wong, DKH=rp00492 | en_US |
dc.identifier.authority | Fung, J=rp00518 | en_US |
dc.identifier.authority | Lai, CL=rp00314 | en_US |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.1111/jgh.12006 | - |
dc.identifier.hkuros | 220782 | en_US |
dc.identifier.volume | 27 | en_US |
dc.identifier.issue | suppl. S5 | en_US |
dc.identifier.spage | 257, abstract P11-162 | en_US |
dc.identifier.epage | 257, abstract P11-162 | en_US |
dc.publisher.place | Australia | - |
dc.customcontrol.immutable | sml 130903 | - |
dc.identifier.issnl | 0815-9319 | - |